Provided by Tiger Fintech (Singapore) Pte. Ltd.

ESSA Pharma

1.48
-0.1000-6.33%
Post-market: 1.46-0.0200-1.35%16:55 EDT
Volume:311.56K
Turnover:471.92K
Market Cap:65.70M
PE:-2.11
High:1.59
Open:1.57
Low:1.43
Close:1.58
Loading ...

Company Profile

Company Name:
ESSA Pharma
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
- -
Office Location:
999 West Broadway,Suite 720,Vancouver,British Columbia,Canada
Zip Code:
V5Z 1K5
Fax:
- -
Introduction:
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Directors

Name
Position
David Parkinson
President, Chief Executive Officer and Director
Richard M. Glickman
Chairman of the Board
Alex Martin
Director
Franklin Berger
Director
Gary Sollis
Director
Lauren Merendino
Director
Marella Thorell
Director
Philip Kantoff
Director
Sanford Zweifach
Director
Scott Requadt
Director

Shareholders

Name
Position
David Parkinson
President, Chief Executive Officer and Director
Peter Virsik
Executive Vice President and Chief Operating Officer
David Wood
Chief Financial Officer
Alessandra Cesano
Vice President and Chief Medical Officer